Continuous epoprostenol therapy and septal defect closure in a patient with severe pulmonary hypertension
β Scribed by Aki Hirabayashi; Katsumasa Miyaji; Teiji Akagi
- Publisher
- John Wiley and Sons
- Year
- 2009
- Tongue
- English
- Weight
- 174 KB
- Volume
- 73
- Category
- Article
- ISSN
- 1522-1946
No coin nor oath required. For personal study only.
π SIMILAR VOLUMES
Pulmonary hypertension associated with increased pulmonary vascular resistance (PVR) and occurring in the setting of portal hypertension is referred to as ''portopulmonary hypertension.'' Intravenous epoprostenol (prostacyclin) is a potent pulmonary and systemic vasodilator with antithrombotic prope
Transcatheter closure of secundum atrial septal
## Abstract Patients with unrepaired pulmonary atresia and ventricular septal defect may develop stenosis of collaterals or shunts to the pulmonary arteries leading to hypoperfusion of lungs and systemic hypoxemia. A 25βyearβold female with pulmonary atresia and ventricular septal defect presented
Objective. To determine the effects of short-term, maximum-tolerated-dose and long-term, optimum-dose iloprost treatment of severe pulmonary hypertension associated with systemic sclerosis (SSc) and the primary antiphospholipid syndrome (APS). Methods. Three patients with SSc and 2 with APS who had